3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
3
Breast
2
Thoracic
1
Conditions
Breast Neoplasms
47
Triple Negative Breast Neoplasms
25
Ovarian Neoplasms
8
Neoplasm Metastasis
8
Melanoma
8
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
5
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Carcinoma, Merkel Cell
3
Lung Neoplasms
2
Kidney Neoplasms
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Interventions
Trastuzumab
18
Radiosurgery
15
Capecitabine
13
Lapatinib
11
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
7
Temozolomide
6
tucatinib
4
pembrolizumab
4
paclitaxel-Angiopep-2 conjugate
4
eribulin
4
Vinorelbine
4
Specimen Handling
4
Paclitaxel
4
Methotrexate
4
Cisplatin
4
sacituzumab govitecan
3
pyrotinib
3
abemaciclib
3
Radiation
3
Fluorodeoxyglucose F18
3
pertuzumab
2
palbociclib
2
neratinib
2
durvalumab
2
cediranib
2
cabazitaxel
2
Sodium Chloride
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
durvalumab
×
Breast
×
Clear all
NCT04711824
2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2
Recruiting
41 enrolled
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled